Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting

Rapport Therapeutics (Nasdaq: RAPP) will present new Phase 2a follow-up data for RAP-219 in focal onset seizures at the 2026 American Academy of Neurology Annual Meeting in Chicago.

Rhea-AI Summary

Rapport Therapeutics (Nasdaq: RAPP) will present new Phase 2a follow-up data for RAP-219 in focal onset seizures at the 2026 American Academy of Neurology Annual Meeting in Chicago.

The podium presentation covers 8-week follow-up efficacy and tolerability results for RAP-219 and is scheduled for April 21, 2026 at 3:54 PM CDT, presented by William W. Motley, M.D.

Argus Apr 1 session

+1.21% close to close Open Argus

Details

News Market Reaction – RAPP

In the Apr 1 session, RAPP gained 1.21%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights upcoming presentation of RAP‑219 Phase 2a and 8‑week follow‑up data in ...

Analysis

This announcement highlights upcoming presentation of RAP‑219 Phase 2a and 8‑week follow‑up data in focal onset seizures at the 2026 AAN meeting, keeping attention on durability and tolerability of prior efficacy signals. Historically, RAP‑219 clinical updates have driven sizable stock moves, both positive and negative. Investors may watch for any new quantitative outcomes from the follow‑up period, updates on Phase 3 timing, and how these data integrate with Rapport’s broader CNS pipeline and recently established $150,000,000 ATM shelf.

Key Figures

Trial phase: Phase 2a Follow-up duration: 8 weeks AAN 2026 dates: April 18–22, 2026 +3 more

Trial phase

Phase 2a

RAP-219 trial in focal onset seizures

Follow-up duration

8 weeks

Follow-up period data to be presented for RAP-219

AAN 2026 dates

April 18–22, 2026

American Academy of Neurology Annual Meeting schedule

Presentation date

April 21, 2026

RAP-219 Phase 2a follow-up podium presentation date

Presentation time CDT

3:54 PM CDT

Scheduled time for AAN scientific platform session

Presentation time EDT

4:54 PM EDT

Corresponding Eastern time for AAN presentation

Previous Clinical trial Reports

5 past events · Latest: Jan 07

Same Type 5 events

1. Jan 07

   Phase 3 initiation

   24h Move

   +8.9%

   Accelerated start of RAP‑219 Phase 3 FOS program and broader pipeline updates.

2. Sep 08

   Phase 2a topline

   24h Move

   +119.2%

   Positive Phase 2a results in FOS with strong seizure reduction and seizure freedom rates.

3. Sep 05

   Data announcement date

   24h Move

   +119.2%

   Scheduled announcement and call details for upcoming RAP‑219 Phase 2a topline results.

4. Jan 09

   Phase 1 data update

   24h Move

   -11.3%

   New Phase 1 data supporting receptor occupancy, tolerability, and CNS targeting for RAP‑219.

5. Jan 09

   Phase 1 data

   24h Move

   -11.3%

   Positive Phase 1 safety and PK results backing dosing for ongoing Phase 2a focal epilepsy trial.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

phase 2a, focal onset seizures, negative allosteric modulator, ampa receptor, +1 more

5 terms

phase 2a medical

"it will present results from its Phase 2a trial of RAP-219 in patients"

Phase 2a is an early stage in testing a new medical treatment or drug, where the main goal is to assess its safety and find the right dosage. For investors, this stage indicates whether the treatment shows initial promise before moving on to larger, more definitive studies; progress here can influence expectations for future development and potential success.

focal onset seizures medical

"Phase 2a trial of RAP-219 in patients with focal onset seizures (FOS)"

Focal onset seizures are seizures that begin in a specific part of the brain and can cause localized symptoms such as brief changes in awareness, unusual sensations, or jerking in one limb; they can sometimes spread to affect the whole brain. Investors care because these seizures define patient groups, influence how drugs and devices are tested and approved, and shape market size, pricing and risk — like a localized outage that requires a targeted fix rather than a whole-system replacement.

negative allosteric modulator medical

"a Potential First-in-Class Negative Allosteric Modulator of γ8 Transmembrane"

A negative allosteric modulator is a drug or compound that binds to a site on a biological receptor different from where the body's natural molecule binds, and reduces the receptor's activity. Think of it as turning down the volume on a signal without cutting it off entirely. For investors, this mechanism can mean more selective effects, potentially fewer side effects, and distinct commercial and regulatory prospects compared with drugs that fully block or mimic a receptor.

ampa receptor medical

"Negative Allosteric Modulator of γ8 Transmembrane AMPA Receptor Regulatory Protein"

A type of protein on nerve cells that responds to the brain chemical glutamate and acts like a fast on/off switch for sending electrical signals between neurons. Because these receptors help control core brain functions such as learning, memory and mood, drugs that enhance or block them can change symptoms in disorders like depression, epilepsy or cognitive decline; news about such drugs or trials often moves biotech and pharmaceutical stocks.

scientific platform session technical

"Session Type: Scientific Platform SessionDate & Time: April 21, 2026"

A scientific platform session is a live, scheduled program at a scientific or medical conference where researchers present and discuss new study results orally to peers and attendees. For investors, these sessions matter because they are often the first public airing of rigorous data about a drug, device or diagnostic — like a product demo presented to experts — and strong or weak findings announced there can change clinical expectations, regulatory outlooks and company valuations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON and SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it will present results from its Phase 2a trial of RAP-219 in patients with focal onset seizures (FOS), including new data from the 8-week follow-up period, in a podium presentation at the upcoming 2026 American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22 in Chicago.

Presentation Details

• Title: Efficacy and Tolerability of RAP-219, a Potential First-in-Class Negative Allosteric Modulator of γ8 Transmembrane AMPA Receptor Regulatory Protein: Impact on RNS Long Episodes and Clinical Seizures
• Presenter: William W. Motley, M.D., RAP-219 Program Leader at Rapport Therapeutics
• Session Type: Scientific Platform Session
• Date & Time: April 21, 2026 at 3:54 PM CDT/4:54 PM EDT

Additional information about the 2026 AAN Annual Meeting is available at www.aan.com.

About RAP-219
RAP-219 is a potential first-in-class, clinical-stage TARPγ8-specific AMPA receptor (AMPAR) negative allosteric modulator (NAM). Whereas AMPARs are distributed widely in the central nervous system, the receptor associated protein (RAP) TARPγ8 is expressed only in discrete brain regions, including the hippocampus and neocortex, where focal seizures often originate. By contrast, TARPγ8 has minimal expression in the hindbrain, where drug effects are often associated with intolerable adverse events. With this precision approach, the Company believes RAP-219 has the potential to provide a differentiated profile as compared to traditional neuroscience medications. Due to the role of AMPA biology in various neurological disorders and the selective targeting of TARPγ8, the Company believes RAP-219 has pipeline-in-a-product potential and is evaluating the compound as a potential treatment for patients with focal onset seizures, primary generalized tonic-clonic seizures, bipolar disorder, and peripheral neuropathic pain.

About Rapport Therapeutics
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological and psychiatric disorders. The Company’s founders made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain, which form the basis of Rapport’s RAP technology platform. The platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport’s precision neuroscience pipeline is anchored by its epilepsy portfolio, including focal onset seizures and primary generalized tonic-clonic seizures, in addition to bipolar mania. The Company is also advancing additional discovery and preclinical programs leveraging its platform, including in chronic pain and migraine and in hearing and vestibular disorders.

Availability of Other Information About Rapport Therapeutics
Rapport Therapeutics uses and intends to continue to use its Investor Relations website and LinkedIn (Rapport Therapeutics) as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company’s Investor Relations website and LinkedIn, in addition to following the Company’s press releases, SEC filings, public conference calls, presentations, and webcasts. The contents of the Company’s website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Contact
Julie DiCarlo
Head of Communications & IR
Rapport Therapeutics
jdicarlo@rapportrx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What will Rapport Therapeutics (RAPP) present at AAN on April 21, 2026?

They will present Phase 2a follow-up results for RAP-219 in focal onset seizures, including 8-week data. According to the company, the podium covers efficacy and tolerability and examines RNS long episodes and clinical seizure outcomes from the trial.

When and where is the RAP-219 presentation by RAPP scheduled at the 2026 AAN Annual Meeting?

The RAP-219 podium presentation is on April 21, 2026 at 3:54 PM CDT in Chicago. According to the company, it is a Scientific Platform Session delivered by William W. Motley, M.D., RAP-219 program leader.

Who is presenting Rapport's RAP-219 Phase 2a follow-up data at AAN 2026?

William W. Motley, M.D. will present the RAP-219 Phase 2a follow-up data on behalf of Rapport. According to the company, he is the RAP-219 program leader and will discuss impact on RNS long episodes and clinical seizures.

What specific endpoints will the RAPP RAP-219 AAN presentation address?

The presentation addresses efficacy and tolerability, focusing on RNS long episodes and clinical seizure measures from the Phase 2a trial. According to the company, the talk includes new data from the 8-week follow-up period.

Is the RAP-219 data at AAN 2026 new and does it include follow-up results?

Yes, the presentation includes new follow-up results from the Phase 2a trial, specifically an 8-week follow-up period. According to the company, these results are part of a podium Scientific Platform Session at AAN 2026.

How can investors view Rapport Therapeutics' RAP-219 presentation from AAN 2026?

Investors can attend the April 21 Scientific Platform Session in Chicago or consult post-conference materials. According to the company, additional meeting information and session details are available through AAN meeting resources.